血清和葡萄糖皮质体调节激酶1在不良心室重塑中的病理作用
Saumya Das1, Takeshi Aiba, Michael Rosenberg
1Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Circulation
|September 29, 2012
概括
血清和葡萄糖皮质激素调节激酶-1 (SGK1) 在心力衰竭中被激活,恶化心脏功能障碍和心律失常. 抑制SGK1可以保护心脏,这表明它是心脏病的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 生物医学研究生物医学研究
背景情况:
- 心力衰竭是死亡率和发病率的重要原因之一.
- 在心力衰竭中,心脏酸丁3-激酶 (PI3K) 信号传递具有悖论性地被激活.
- 下游效应因子血清和葡萄糖皮质激素调节激酶-1 (SGK1) 在心力衰竭中进行了研究.
研究的目的:
- 为了研究SGK1在心力衰竭的发病过程中的作用.
- 为了确定SGK1是否是心脏病的潜在治疗点.
主要方法:
- 在小鼠模型中利用了构成性活跃或主导负SGK1的心脏特异表达.
- 评估死亡率,心脏功能,心室节律失常和心脏道功能.
- 研究了罗纳拉对SGK1诱导的前节律失常效应的影响.
- 评估了SGK1抑制对血液动力学压力后心脏纤维化和心力衰竭的影响.
主要成果:
- 发现心脏SGK1在人类和小鼠心力衰竭中被激活.
- 在小鼠中,SGK1的心脏特异激活导致死亡率增加,心脏功能障碍和心室节律失常.
- SGK1诱导的心律失常与心脏通道的改变有关,并被罗纳拉逆转.
- 心脏特异性抑制SGK1受保护小鼠的纤维化,心力衰竭和血动力应激后的通道变化.
结论:
- 在心力衰竭中,SGK1对于不良心室重塑的关键特征既必要又足够.
- SGK1代表了心脏病的潜在新型治疗点.
相关概念视频
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...